Repligen (NASDAQ:RGEN) Downgraded by BidaskClub to Buy

BidaskClub downgraded shares of Repligen (NASDAQ:RGEN) from a strong-buy rating to a buy rating in a report issued on Wednesday morning, BidAskClub reports.

A number of other brokerages have also weighed in on RGEN. Craig Hallum upped their target price on Repligen from $80.00 to $108.00 and gave the stock a buy rating in a research report on Monday, August 5th. First Analysis upped their target price on Repligen from $95.00 to $107.00 and gave the stock an outperform rating in a research report on Wednesday, August 28th. HC Wainwright reaffirmed a buy rating and set a $110.00 target price on shares of Repligen in a research report on Monday, August 12th. ValuEngine lowered Repligen from a strong-buy rating to a buy rating in a research report on Thursday, August 1st. Finally, Zacks Investment Research lowered Repligen from a buy rating to a hold rating in a research report on Wednesday, August 7th. One equities research analyst has rated the stock with a hold rating and ten have given a buy rating to the company. Repligen has an average rating of Buy and an average target price of $101.17.

RGEN traded down $0.87 during trading on Wednesday, hitting $79.01. The company’s stock had a trading volume of 856,130 shares, compared to its average volume of 463,417. Repligen has a twelve month low of $48.26 and a twelve month high of $99.25. The company has a quick ratio of 1.88, a current ratio of 2.25 and a debt-to-equity ratio of 0.02. The stock’s fifty day moving average price is $91.31 and its 200-day moving average price is $74.42. The firm has a market capitalization of $4.18 billion, a P/E ratio of 108.23, a PEG ratio of 4.82 and a beta of 1.16.



Repligen (NASDAQ:RGEN) last issued its quarterly earnings results on Thursday, August 1st. The biotechnology company reported $0.31 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.25 by $0.06. Repligen had a return on equity of 6.92% and a net margin of 11.42%. The firm had revenue of $70.70 million for the quarter, compared to analyst estimates of $65.47 million. During the same period in the previous year, the firm earned $0.14 earnings per share. The company’s revenue was up 48.1% compared to the same quarter last year. Equities research analysts expect that Repligen will post 0.97 EPS for the current fiscal year.

In related news, CEO Anthony Hunt sold 12,094 shares of the company’s stock in a transaction on Monday, September 9th. The stock was sold at an average price of $82.40, for a total transaction of $996,545.60. Following the completion of the sale, the chief executive officer now owns 210,976 shares in the company, valued at $17,384,422.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Karen A. Dawes sold 1,295 shares of the company’s stock in a transaction on Monday, June 17th. The stock was sold at an average price of $77.35, for a total value of $100,168.25. Following the sale, the director now owns 118,329 shares of the company’s stock, valued at approximately $9,152,748.15. The disclosure for this sale can be found here. 1.70% of the stock is owned by corporate insiders.

Institutional investors have recently made changes to their positions in the stock. BNP Paribas Arbitrage SA grew its holdings in Repligen by 314.6% during the first quarter. BNP Paribas Arbitrage SA now owns 8,984 shares of the biotechnology company’s stock worth $531,000 after buying an additional 6,817 shares in the last quarter. New York State Common Retirement Fund grew its holdings in Repligen by 3.0% during the first quarter. New York State Common Retirement Fund now owns 164,242 shares of the biotechnology company’s stock worth $9,703,000 after buying an additional 4,708 shares in the last quarter. Redhawk Wealth Advisors Inc. bought a new stake in Repligen during the second quarter worth $462,000. Navellier & Associates Inc bought a new stake in Repligen during the second quarter worth $647,000. Finally, Westpac Banking Corp grew its holdings in Repligen by 9.3% during the first quarter. Westpac Banking Corp now owns 94,885 shares of the biotechnology company’s stock worth $5,606,000 after buying an additional 8,100 shares in the last quarter. Institutional investors and hedge funds own 88.66% of the company’s stock.

Repligen Company Profile

Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process in North America, Europe, APAC, and internationally. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media.

Read More: What is Liquidity?

Analyst Recommendations for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.